Surfus JE - Search Results

1

MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells.

Fisch P, Oettel K, Fudim N, Surfus JE, Malkovsky M, Sondel PM. Fisch P, et al. Among authors: surfus je. J Immunol. 1992 Apr 15;148(8):2315-23. J Immunol. 1992. PMID: 1532810

2

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM. Hank JA, et al. Cancer Res. 1990 Sep 1;50(17):5234-9. Cancer Res. 1990. PMID: 2386933

3

Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.

Hank JA, Surfus J, Gan J, Albertini M, Lindstrom M, Schiller JH, Hotton KM, Khorsand M, Sondel PM. Hank JA, et al. Clin Cancer Res. 1999 Feb;5(2):281-9. Clin Cancer Res. 1999. PMID: 10037176 Clinical Trial.

4

Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.

Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM. Hank JA, et al. Among authors: surfus je. Cancer Immunol Immunother. 1990;31(1):53-9. doi: 10.1007/BF01742496. Cancer Immunol Immunother. 1990. PMID: 2306756 Free PMC article.

5

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. Surfus JE, et al. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91. doi: 10.1097/00002371-199605000-00003. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8811493

6

TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.

Nicolet CM, Siegel DH, Surfus JE, Sondel PM. Nicolet CM, et al. Among authors: surfus je. Tumour Biol. 1997;18(6):356-66. doi: 10.1159/000218050. Tumour Biol. 1997. PMID: 9372869

7

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM. Hank JA, et al. Among authors: surfus je. Clin Cancer Res. 1996 Dec;2(12):1951-9. Clin Cancer Res. 1996. PMID: 9816154

8

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM. Neal ZC, et al. Cancer Immunol Immunother. 2004 Jan;53(1):41-52. doi: 10.1007/s00262-003-0435-2. Epub 2003 Sep 18. Cancer Immunol Immunother. 2004. PMID: 14504825 Free PMC article.

9

Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.

Hank JA, Surfus JE, Gan J, Ostendorf A, Gillies SD, Sondel PM. Hank JA, et al. Among authors: surfus je. Methods Mol Med. 2003;85:123-31. doi: 10.1385/1-59259-380-1:123. Methods Mol Med. 2003. PMID: 12710203 Review. No abstract available.

10

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.

Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Reisfeld RA, Schiller JH, Sondel PM. Albertini MR, et al. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95. doi: 10.1097/00002371-199607000-00004. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8877722

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters